Zolbetuximab regimen extends PFS in metastatic gastric, gastroesophageal junction cancers

The addition of zolbetuximab to chemotherapy improved PFS among certain patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, according to the agent’s manufacturer.Zolbetuximab (IMAB362, Astellas) is an investigational chimeric IgG1 monoclonal antibody that targets and binds to Claudin 18.2 (CLDN18.2).The double-blind, randomized phase 3 GLOW trial assessed the efficacy and safety of zolbetuximab plus CAPOX— a combination chemotherapy regimen that includes capecitabine and oxaliplatin — as first-line treatment forRead More

Generated by Feedzy